Logistics of Adopting¹⁷⁷Lu-Vipivotide Tetraxetan Therapy in a Community-Based Hospital Setting

Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, ¹⁷⁷Lu-vipivotide tetraxetan was U.S. Food and Drug Administration-approved for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. <b>Methods:</b> Although preliminary data for ¹⁷⁷Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating ¹⁷⁷Lu-vipivotide tetraxetan into non-academic-based clinical practices. <b>Results:</b> This article presents a multidisciplinary practice implementation workflow for ¹⁷⁷Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. <b>Conclusion:</b> The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically ¹⁷⁷Lu-vipivotide tetraxetan.